

PROTOCOL

Motivating Physical Activity with a Walking Exercise Behaviour Intervention and Pain Management Remotely in Intermittent Claudication (MAVERIC): protocol for a randomised controlled feasibility trial

Carroll SP,¹ Gray SR,² Wood L,³ Bearne L,⁴ Seenan C¹

1. Department of Physiotherapy and Paramedicine, School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK

2. School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

3. Department of Biological and Biomedical Sciences, School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK

4. Population Health Research Institute, St George's, University of London, London, UK

Corresponding author:

Sean Paul Carroll
Department of Physiotherapy and Paramedicine, School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, G4 0BA, UK
Email: sean.carroll@gcu.ac.uk

Received: 6th March 2024

Accepted: 3rd May 2024

Online: 16th May 2024

Plain English Summary

Why we are undertaking this research: Peripheral arterial disease (PAD) occurs when the arteries in the legs narrow and harden. People with PAD have a lower quality of life and are at risk of heart attack and stroke. Research suggests that people with PAD should increase their walking as with advice given for other heart issues. Yet people with PAD receive less exercise and treatment than those with other heart problems despite the benefits to leg pain, walking function and health. For those with PAD, walking can be hard because it hurts. Our studies have found that a small pain-easing device can help people walk further. We also found that helping people know how to manage their PAD and setting exercise goals can increase walking and well-being. Since not all people can travel for these services, we are looking to see if a pain-easing device and online meetings with a physiotherapist can work.

What we aim to do: We will test if an online walking exercise behaviour programme and using a transcutaneous electrical nerve stimulation (TENS) device can help people with PAD be more active. This involves completing a walking programme at home with support from two video and two telephone sessions with a physiotherapist and using a TENS device to reduce any walking pain. We will check how these compare to usual care offered at this health board. Usual care consists of medication, lifestyle and walking advice or plan. Patients from the vascular units will be invited to join the study. If they are suitable they will be put into a group by chance either trying the new methods or usual care alone. A device will track how much walking each person does. They will also share their views through surveys and feedback. This will help to better the study and programme before being tested on a larger scale.

Abstract

Background: Physical activity (PA) through walking exercise improves functional capacity and quality of life and provides secondary prevention benefits in individuals with peripheral arterial disease (PAD) and intermittent claudication (IC). However, there are many barriers to uptake and maintenance of PA in this population including pain and limited motivation. The aim of this study is to test the feasibility and acceptability of delivering a clinical trial to evaluate the effect of using a walking exercise behaviour change intervention, modified to include the use of a transcutaneous electrical nerve stimulation (TENS) device for non-invasive pain management, to increase walking-based PA in individuals with PAD and IC in comparison with usual care.

Methods: This is a randomised controlled analysis-blinded feasibility study with two parallel groups. We will recruit 48 adults with PAD and IC from NHS Lanarkshire vascular service. Inclusion criteria are: PAD (ankle brachial pressure index ≤ 0.90) and stable IC for ≥ 3 months, being able and willing to participate, and to provide informed consent. Participants will be randomly assigned 1:1 to intervention plus usual care or usual care alone. Usual care includes best medical therapy, information on PAD, walking advice or home exercise programme, and managing risk factors. The intervention consists of a home-based, walking exercise behaviour change intervention (MOSAIC), adapted for remote delivery, and includes non-pharmacological pain management through a TENS device. Feasibility and exploratory outcomes will be assessed at baseline, after 6 and 12 weeks of intervention, and at 6 and 12 months follow-up. The primary outcomes are trial process and intervention feasibility, as well as

intervention acceptability measured using rates of participant recruitment and retention, intervention adherence, and the Theoretical framework of Acceptability questionnaire. Exploratory outcomes include daily PA and patient-reported outcomes including quality of life, pain self-efficacy and catastrophising, and walking impairment pain intensity and quality.

Conclusion: This trial will evaluate the feasibility and acceptability of a remotely delivered walking exercise behaviour change intervention adapted to include the use of a TENS device to improve PA in individuals with PAD and IC.

Key words: peripheral arterial disease, physical activity, behaviour change, walking exercise, transcutaneous electrical nerve stimulation

Trial Registration Number: ClinicalTrials.gov Identifier: NCT06114732

Introduction

Peripheral arterial disease (PAD) affects approximately one in five people aged >60 years.^{1,2} In addition, 40–75% of these people experience intermittent claudication (IC), a chronic manifestation of PAD which commonly presents as limb pain and reduced exercise tolerance.^{3,4} People with PAD and IC experience disability and impaired quality of life due to reduced physical capacity compared with age- and sex-matched controls.^{5,6} Overall, this causes a significant burden to individuals with the disease, as well as wider economic costs and service costs to the National Health Service (NHS) in terms of loss of healthy life-years and treatment.^{7–10}

Improving physical activity (PA) is particularly important in individuals with IC as lower PA levels have been recognised as a strong predictor of increased morbidity and mortality in this population.^{11,12} National Institute for Health and Care Excellence (NICE) guidance recommends Supervised Exercise Therapy (SET) as a primary treatment for IC with established efficacy in increasing PA, walking distance and improving quality of life, contributing to secondary prevention of major adverse cardiovascular events (MACE).^{4,13} However, guideline standard SET is available in only one in four vascular services in the UK.¹⁴ Moreover, where SET is available, uptake and adherence are limited due to reduced mobility from limb pain or low walking capacity, and this may be further restricted with variation in local service provision within a hub-and-spoke healthcare model.¹⁵ This reflects a severe inequality in healthcare to the 17–30% of people in the UK who reside in rural communities and those with increased level of disability.^{16,17} Therefore, in light of the prevalence of PAD, the constraints of healthcare resources and variation in provision of services nationally, there is an urgent need for the development of easily accessible and scalable alternatives to conventional SET.

Due to the extrinsic and intrinsic barriers to participation in PA in people with IC, it is vital that, as well as navigating the limitations of SET, the interventions also improve health literacy, illness perception and self-efficacy.^{18,19} There is some evidence that the self-management of IC using behaviour change principles may be effective in addressing issues with self-efficacy, health literacy and uptake of walking exercise.²⁰ Recently, following participation in the walking-based behaviour intervention Motivating Structured

Walking Activity in People with Intermittent Claudication (MOSAIC),²¹ people with PAD (n=190) were able to walk further at 3-month follow-up and reported improvements in other functional and quality of life outcomes.²² The intervention included two in-person and two telephone sessions delivered by physiotherapists over 3 months. MOSAIC has the potential to be delivered remotely to ensure that people with PAD can continue to take part in the intervention even if they live within rural communities with limited transport links or if SET is not provided locally. With the increasing access to the internet, even in low-income groups, the practicality of remote delivery of interventions on a large scale may be possible.²³

While it is promising that novel accessible and scalable alternatives may exist to SET, for people with IC to gain the benefits of secondary prevention through PA, exercising beyond the point when pain occurs is recommended.²⁴ This represents another barrier to engagement in PA.^{25,26} Despite this, a recent systematic review²⁷ found that pain management as a route to facilitate exercise and PA has rarely been explored. Recent work has suggested that the use of transcutaneous electrical nerve stimulation (TENS) applied to the lower limb during walking on a treadmill can improve absolute claudication distance above placebo.²⁸ Moreover, the home use of TENS may contribute to improvement in PA in individuals with IC.^{28,29}

By managing limb pain and facilitating walking exercise behaviour change, MOSAIC adapted to include TENS may have the potential to help increase walking-based PA and walking capacity in people with IC.^{22,28} However, the combination of a remotely delivered walking exercise behaviour change intervention that includes TENS has not previously been evaluated. Prior to assessing the clinical and cost effectiveness of the intervention in a suitably powered randomised controlled trial (RCT), outcome data from which the sample size of a clinical trial could be estimated, the acceptability and feasibility of both trial processes and procedures as well as remote delivery of MOSAIC with a TENS device must be assessed and refined if appropriate.³⁰ Therefore, the aim of this randomised controlled feasibility trial is to determine the feasibility and acceptability of conducting a trial investigating the effectiveness of a remote walking exercise behaviour change

intervention (MOSAIC) adapted to include TENS in people with PAD compared with usual care.

Methods

Research objectives

1. Assess the feasibility of conducting an RCT of a remotely delivered walking exercise behaviour intervention modified to include TENS in people with IC.
2. Measure participant recruitment, retention and attrition.
3. Measure outcome completion, attendance at appointments, total accelerometer wear time and usage of TENS device.
4. Measure protocol adherence and safety.
5. Conduct semi-structured interviews with intervention completers to assess acceptability and lived experience of the trial processes and intervention.
6. Explore changes in physical activity and quality of life outcomes from which the sample size of a definitive trial could be estimated.
7. Explore participants' experiences and perceptions of the interventions and trial procedures.

Study design

This is an assessor blinded randomised feasibility trial. Forty-eight adults with PAD and IC will be randomised to one of two arms: remote MOSAIC adapted to include TENS plus usual care or usual care alone (Figure 1). The setting in which the trial processes and intervention consultations will take place is within the home or other convenient private area suitable for telehealth consultation. This protocol follows the guidelines recommended by the Standard Protocol Items for Interventional Trials and recommended CONSORT extension to randomised feasibility trials (see Appendix 1 and 2 online at www.jvsgbi.com).

Inclusion and exclusion criteria

Patients within the NHS Lanarkshire Vascular Outpatient Service with either a clinical diagnosis of PAD by a vascular specialist, an ankle brachial pressure index (ABPI) ≤ 0.9 at rest or evidence of PAD on Doppler ultrasound or angiography will be invited to participate in the


trial. Inclusion and exclusion criteria are listed in Figure 1. Symptomatic stable IC (stage II Fontaine Classification) will be determined by a report of symptoms on the San Diego Claudication Questionnaire (SDCQ)³¹ and clinical diagnosis by a vascular specialist including ABPI of <0.9 . Participants with critical limb ischaemia (rest pain, ulceration, gangrene) and those in whom lower limb revascularisation is planned within the intervention period will be excluded. Patients who are unable to give informed consent, are participating in another medically prescribed exercise intervention, are unable to walk due to co-existing medical morbidities or those with no internet or computer device for video consultations will be excluded.

Study procedures

Sampling and recruitment

Patients with PAD and IC within NHS Lanarkshire will be invited to take part in this study from February 2024 at the vascular outpatient service by the allied health professional or nurse undertaking the consultation. This is the primary method of recruitment; however, if the recruitment rate is $<5\%$ of the required sample after 2 months, a screening questionnaire will be used by a member of the vascular service when examining the clinic lists of

Figure 1 Study flow diagram.



the last 2 years to identify eligible participants attending the vascular outpatient claudication clinic. They will send by post an expression of interest letter along with a participant information sheet which contains a telephone contact number if the patient wishes to opt into the study.

A total sample size of 48 was calculated based on the proportions of uptake, attendance and compliance from the intervention arm.^{22,28} An overall sample size of 43 participants was calculated which was increased to 48 participants to allow for potential attrition.³²

Randomisation

Participants will be block randomised in a 1:1 ratio to either MOSAIC + TENS or usual care. The randomisation will not be conducted by researchers involved in recruitment or outcome assessment. Allocations will be prepared using a random number generator and kept in sealed opaque envelopes prepared by a researcher who is independent of the study team. The envelopes will remain unopened until allocation by the Principal Investigator (PI) at the first contact following baseline data collection.

Control group

Participants will receive usual care and walking/exercise advice from the vascular and claudication service at NHS Lanarkshire. This will be a pragmatic control arm as individual treatment may vary between participants. Usual care follows standard clinical guidance and often involves offering information on PAD and changes in lifestyle (eg, quitting smoking, managing diet and weight), walking advice or home exercise programme, managing risk factors which includes adjusting lipids, using statin and antiplatelet treatments or medication to enhance leg symptoms (vasodilators such as naftidrofuryl oxalate).⁴ In NHS Lanarkshire people with PAD are usually diagnosed and treated in primary care within a network of Community Claudication Clinics, with onward referral to vascular outpatient clinics for further investigation and treatment as necessary.

Intervention group

The adapted walking exercise behaviour intervention (based on MOSAIC)^{21,22} comprises two 60 min consultations completed by video call (weeks 1 and 2) and two 20 min follow-up telephone calls (weeks 6 and 12). The content of each session is standardised and incorporates evidence-based behaviour change techniques to facilitate understanding and commitment to walking exercise. Sessions will be tailored based on participants' knowledge, goals, symptoms and current walking using a motivational interviewing approach.³³ The session is delivered by the PI who is educated in motivational interviewing techniques.

One week in advance of the first video consultation an interactive manual containing worksheets and a walking diary will be posted out as part of the modified walking exercise behavioural intervention. During the first video consultation the participants, in addition to using the MOSAIC materials in the consultation, will be offered a TENS device as an option to manage their leg pain during walking exercise and a pedometer to self-monitor their step count,

using the motivational interviewing approach 'elicit-provide-elicit'.³³ If they opt to use the TENS device or pedometer it will be posted to their home address with an instruction booklet for the device. There will be an opportunity to query or troubleshoot TENS device usage at the next video consultation one week after the first video consultation. The intervention group will receive high-frequency TENS (120 Hz, 200 μ s and a participant-determined intensity of 'strong but comfortable'), as this was found in a proof-of-concept study to increase the distance walked in people with IC before reaching their pain tolerance and prolonged time to reach onset of pain (compared with low-frequency TENS).²⁸

As part of the second video consultation, walking plans will be agreed collaboratively between the participant and the physiotherapist and include progressive individualised targets for walking frequency, intensity and duration to achieve at least the recommended walking guidance for IC (30–50 min of walking three times/week at an intensity that elicits pain within 3–5 min).²⁴ Options to use the TENS device will be discussed and agreed alongside walking goals and plans in the second video consultation if the participant agrees to this. Walking plans, progress and goals will be reviewed at weeks 6 and 12 during 20-min telephone booster sessions.

Outcome measures

Feasibility and acceptability outcomes

The study recruitment rate will be recorded by logging reasons for non-eligibility and non-recruitment of eligible participants using the study screening log. Uptake and adherence to intervention sessions by participants will be measured by attendance at appointments, withdrawal from study, TENS usage (via in-built memory of the device and a self-reported TENS diary) and administering the Theoretical Framework of Acceptability questionnaire at the trial endpoint.³⁴ In addition, a purposive sample of participants will be invited to attend a semi-structured interview regarding their lived experience of the trial and interventions. Adverse events will be monitored, recorded in a study log and followed up if required. Data will be collected by the PI at all time points.

Exploratory outcomes

The habitual PA of participants will be recorded by a trial axial accelerometer, the activPAL™, worn for 7 days and the following outcomes extrapolated from the accelerometry data: total daily steps, total duration of walking, total daily time spent sitting, and event-based claudication index (ECBI; the ratio of walking events to upright events participants undertake in a day).³⁵ Three days or 72 hours of continuous wear of activPAL™ data at each time point will be the minimum for including a participant's activPAL™ data in the exploratory analysis. Pain-related quality, intensity, self-efficacy and catastrophising will be assessed using patient-reported outcome measures (PROMs): the Short Form-McGill Pain Questionnaire (SF-MCQ)-2,³⁶ a Visual Analogue Scale (VAS) of Intensity of Pain, Pain Self-Efficacy (PSEQ)³⁷ and Pain Catastrophizing Scale (PCS).³⁸ Likewise, quality of life will be assessed using PROMs: the

Table 1 Schedule of enrolment, interventions and assessments.

Study period								
	Enrolment	Allocation	Post-allocation					Close-out
TIMEPOINT	-t ₂	0	t ₁	t ₂	T ₆	T ₁₂	T ₁₃	T ₅₂
ENROLMENT:								
Eligibility screen	X	X						
Informed consent	X							
Allocation		X						
INTERVENTIONS:								
MOSAIC + TENS			←————→					
Control			←————→					
ASSESSMENTS:								
Feasibility measures	X	X			X	X		X
Acceptability measures	X	X			X	X		
Physical activity behaviour		X			X	X		X
Quality of life		X			X	X		X
Pain intensity		X			X	X		X
Pain quality		X			X	X		X
Pain self-efficacy		X			X	X		X
Pain catastrophising		X			X	X		X
Adverse events						X		
Semi-structured interview							X	

MOSAIC, Motivating Structured Walking Activity in People with Intermittent Claudication; TENS, transcutaneous electrical nerve stimulation.

Intermittent Claudication Questionnaire (ICQ)³⁹ and the EQ-5D-3L. Data collection time points for each outcome are shown in Table 1. All outcome assessment devices and measures are returned by post so, to maintain blinded data analysis, materials will be assigned a unique code and any identifying information removed prior to data entry and analysis by a researcher outwith the study team.

Evaluation of intervention delivery fidelity

To assess fidelity to the intervention, all intervention sessions will be audio recorded with permission from the participant. A random sample of 10–20% of recorded sessions will be assessed by a member of the study team from the MOSAIC trial, to assess the extent that mandatory components of each session were delivered as intended. Segments of 20 min, chosen at random from the intervention sessions sampled, will undergo evaluation for the physiotherapist’s effectiveness in motivational interviewing using the Motivational Interviewing Treatment Integrity scale.⁴⁰ This includes assessing relational proficiency on a Likert scale, where a score of 3.5 out of 5 suggests an acceptable level of interpersonal style and technical proficiency, and a score of 3 out of 5 indicates an adequate technique.

Trial schedule

Baseline assessment

Written informed consent will be recorded and baseline measurements will be conducted including questionnaires and fitting of the activPAL™ monitor remotely over video call with the PI. These will be posted out to the participant with an information sheet and further instruction can be sought at the video call with the PI. Paper copies of the PROMs will be posted back using a pre-paid envelope at baseline, week 6 and week 12. These will be collected, anonymised and given a unique identifier by a member of the study team not delivering the intervention or conducting data analysis. Participants will also return the activPAL™ after 1 week of wear via a pre-paid envelope. After this point, participants will be randomised to either intervention or usual care as described under study procedures.

Weeks 6 and 12 assessment

The second and third data collection points (6 and 12 weeks) will occur following a 20 min telephone ‘booster’ session and review of progress and goals for the intervention. This will be a repeat of the outcome assessment conducted at baseline; however, the Theoretical Framework of Acceptability questionnaire will only be administered at week 12 (intervention end point). The usual care group will only be contacted at 6 weeks and 12 weeks by the research team to post the questionnaires and video fitting of the activPAL™ monitor.

Qualitative interviews and follow-up assessment

At the intervention end point a purposive sample of participants will be invited to an online semi-structured interview session, which will be implemented within 1–3 weeks after the end of the intervention. The setting in which the qualitative interviews will take place is within the home or other convenient private area. The follow-up outcome assessment will be at 6 and 12 months for all groups. This will be a repeat of the outcomes at the baseline assessment.

Data analysis

Analyses will follow the intention-to-treat principle. Secondary per protocol analyses will also be performed. To ensure blinded analysis by the PI, all outcome data received from participants will be sent to the Chief Investigator (CS) who will conceal the group allocation and a unique code in place of identifiable information (eg, participant name). This anonymised data will then be input into an electronic Excel spreadsheet and the Principal Investigator (SC) will conduct data analysis independently to remain blinded. All data will be summarised in accordance with the CONSORT guidelines.⁴¹ Descriptive statistics will be used to describe demographics and baseline characteristics of each outcome, as well as to compare the outcomes at each time point between and within groups.

Feasibility and acceptability analysis

To determine the feasibility of conducting an efficacy trial, descriptive statistics will be used to report the number and proportion of participants who meet the inclusion criteria, who consented to participating, and who dropped out during the trial.

Feasibility of trial processes in the remote setting will be derived from a participant's attendance at appointments, follow-up calls, rate of outcome measure completion, total accelerometer wear time and, if applicable, self-reported and internal memory recorded use of the TENS device.

Recordings from the semi-structured interviews will be transcribed verbatim and analysed using interpretive thematic analysis by the lead author.⁴² The researchers will provide written transcripts to the participants to check the accuracy of the transcription. Provisional themes will be discussed with the wider research team with reference to an audit trail, and processes refined if required to agree on and identify the final labeling of themes. In order to manage the data and undertake analysis, NVivo V20 (QSR International Pty Ltd) will be used.

Exploratory analysis

Between-group comparisons for walking outcome measures and group continuous measures will be summarized using mean and standard deviation, or median and interquartile range if the distribution is skewed. To compare different groups allocated to each intervention, an analysis of variance will be used, or a Kruskal–Wallis test if the data are non-parametric. The Theoretical Framework of Acceptability questionnaire scores will be compared between groups cross-sectionally at the intervention end point using a Mann–Whitney U test. Within-group comparisons longitudinally will be examined using a repeated measures analysis, or non-parametric equivalent if appropriate. Analysis will be blinded by a member outwith the study team anonymising the dataset.

Unblinding will be permitted in the event of a spontaneously reported adverse event or unintended effect of trial intervention that requires liaison with the participant's medical care team. In this event, this will be logged on the trial adverse event form and the sponsor and local NHS Research and Development office informed. If appropriate, the participant will be removed from the trial.

Data management

Data will remain confidential and stored securely at Glasgow Caledonian University in accordance with the Data Protection Act and General Data Protection Regulation. Electronic data will be pseudo-anonymised and stored on a password-protected database on a secure device at Glasgow Caledonian University. Only named investigators will have access to the data. All paper documentation including signed informed consent forms will be kept in a secure locked filing cabinet at Glasgow Caledonian University. Data will be retained in accordance with the Good Clinical Practice guidelines or local regulations, whichever specifies a longer retention time.

Trial Management Group

The trial will be coordinated from Glasgow Caledonian University by the Trial Management Group. This will consist of the co-investigators, NHS Lanarkshire Claudication Steering Group chair, Service Manager,

KEY MESSAGES

- We plan to assess the feasibility and acceptability of a remotely delivered walking-based behaviour intervention adapted to include non-pharmacological pain management using TENS.
- This will allow us to determine if any refinements are required to remote delivery of the intervention, which is the first step in testing the behaviour change intervention for telehealth implementation in the NHS.
- If feasibility and acceptability is demonstrated through this trial, exploratory outcomes will inform the sample size for a future definitive randomised controlled trial evaluating effectiveness.

and a person with PAD as a patient and public involvement (PPI) representative. The role of the group is to monitor the conduct and progress of the trial, ensure that the protocol is adhered to and take appropriate action to safeguard participants and the quality of the trial itself. The group will meet every 3 months via video conference.

Study registration and ethical approval

The West of Scotland Research Ethics Committee provided approval for this study (Reference: 23/WS/0147) on 30 October 2023 and the study was subsequently registered on ClinicalTrials.gov (Identifier: NCT06114732). The research will be carried out following the principles of the Declaration of Helsinki. Those who qualify for inclusion will be asked to provide written informed consent before taking part in the study. Each participant will be reminded of their right to withdraw. Glasgow Caledonian University is the sponsor for this feasibility trial.

Discussion

People with PAD and IC face a loss of healthy life-years, as well as a heightened risk of MACEs, hospitalisation and mortality.^{1–5} Finding accessible, acceptable and scalable methods to support increasing walking-based PA for people with this condition is crucial, given the disease burden for individuals and their families and the economic demand on the NHS.^{7–10} The need for this is amplified when considering the significant barriers to walking that prevent uptake and adherence, both intrinsic (self-efficacy, knowledge of PA as beneficial and limb pain) and extrinsic (geography, accessibility to an exercise professional or service).^{25,26}

Altogether, these findings emphasise the need for self-management interventions that are accessible and address both pain management and walking-related behaviour change. MAVERIC is a novel combination of a remotely delivered walking exercise behaviour change intervention (MOSAIC)²² adapted to include TENS²⁸ for pain management. The intervention aims to address the barriers to physical activity in people with PAD and IC. This is the first step in testing the behaviour change and pain management intervention for telehealth implementation in the NHS.

If feasibility and acceptability of trial processes and intervention are demonstrated in this study, an appropriately powered RCT will aim to test the effectiveness on walking-based PA in people with IC. Despite the novel approach due to the use of internet and of a smart device/computer in receiving the intervention, there may be some socioeconomic bias in the sample. Additionally, the exclusion of ABPI measurement with exercise testing may have reduced sensitivity of the recruitment strategy.

Trial status: Protocol version 1.1: 30 October 2023. Recruitment beginning February 2024 until required numbers are reached.

Conflicts of interest: The authors have none to declare.

Funding: This project is being completed as part of a fully funded PhD with the School of Health and Life Sciences, Glasgow Caledonian University. This study is partially funded by the Scottish Heart and Arterial Risk Prevention (SHARP) Research Project Grants. The funders have no role in the study design, collection, management, analysis or interpretation of data; writing of this report; or decision to submit this report for publication.

Acknowledgements: The authors would like to thank colleagues at NHS Lanarkshire: Colette Ramsay, Abi Campbell, Prof Eamonn Brankin, Prof Roy Scott, Mr Tamim Siddiqi, Mr Alex Vesey, and the Claudication Steering Group, alongside Raymond Hamill, Frances McCulloch & Lorraine Quinn of Research & Development.

Author contributions: The protocol was written by SC with guidance from SG, LW, LB and CS. All authors have approved the manuscript.

Ethical approval: Ethical approval was given by the Glasgow Caledonian University Health and Life Sciences Ethics Committee. Health Research Authority (HRA) approval has been obtained and Research Ethics Committee favourable opinion has been granted by the West of Scotland REC on 30 October 2023 (reference: 23/WS/0147). Glasgow Caledonian University is the sponsor for this feasibility trial.

Reviewer acknowledgement: *JVSGBI* thanks Amy Harwood, Department of Sport and Exercise Science, Institute of Sport, Manchester Metropolitan University and the Editorial team for their contribution to the peer review of this work.

References

- Song P, Rudan D, Zhu Y, *et al*. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. *Lancet Glob Health* 2019;**7**:e1020–e1030. [https://doi.org/10.1016/S2214-109X\(19\)30255-4](https://doi.org/10.1016/S2214-109X(19)30255-4)
- Fowkes FGR, Rudan D, Rudan I, *et al*. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. *Lancet* 2013;**382**:1329–40. [https://doi.org/10.1016/S0140-6736\(13\)61249-0](https://doi.org/10.1016/S0140-6736(13)61249-0)
- Norgren L, Hiatt WR, Dormandy JA, *et al*. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg* 2007;**45**(Suppl):S5–S67. <https://doi.org/10.1016/j.jvs.2006.12.037>
- National Institute for Health and Care Excellence (NICE). Peripheral arterial disease: diagnosis and management. Clinical guideline [CG147]. December 2020. <https://www.nice.org.uk/guidance/cg147> [accessed 12 December 2023].
- Marrett E, DiBonaventura M, daCosta ZQ. Burden of peripheral arterial disease in Europe and the United States: a patient survey. *Health Qual Life Outcomes* 2013;**11**:175. <https://doi.org/10.1186/1477-7525-11-175>
- Roger VL, Go AS, Lloyd-Jones DM, *et al*. Heart disease and stroke statistics—2012 update. *Circulation* 2012;**125**:e2–e220. <https://doi.org/10.1161/CIR.0b013e31823ac046>
- Polonsky TS, McDermott MM. Lower extremity peripheral artery disease without chronic limb-threatening ischemia. *JAMA* 2021;**325**:2188–98. <https://doi.org/10.1001/jama.2021.2126>
- Drummond M. Socioeconomic impact of peripheral vascular disease. *Atherosclerosis* 1997;**131**(Suppl):S33–S34. [https://doi.org/10.1016/s0021-9150\(97\)06123-6](https://doi.org/10.1016/s0021-9150(97)06123-6)
- Peach G, Griffin M, Jones KG, Thompson MM, Hinchcliffe RJ. Diagnosis and management of peripheral arterial disease. *BMJ* 2012;**345**:e5208. <https://doi.org/10.1136/bmj.e5208>
- Sampson UKA, Fowkes FGR, McDermott MM, *et al*. Global and regional burden of death and disability from peripheral artery disease 21 world regions, 1990 to 2010. *Glob Heart* 2014;**9**:145–58.e21. <https://doi.org/10.1016/j.ghheart.2013.12.008>
- Gardner AW, Addison O, Katzel LI, *et al*. Association between physical activity and mortality in patients with claudication. *Med Sci Sports Exerc* 2021;**53**:732–9. <https://doi.org/10.1249/MSS.0000000000002526>
- Leeper NJ, Myers J, Zhou M, *et al*. Exercise capacity is the strongest predictor of mortality in patients with peripheral arterial disease. *J Vasc Surg* 2013;**57**:728–33. <https://doi.org/10.1016/j.jvs.2012.07.051>
- Campia U, Gerhard-Herman M, Piazza G, Goldhaber SZ. Peripheral artery disease: past, present, and future. *Am J Med* 2019;**132**:1133–41. <https://doi.org/10.1016/j.amjmed.2019.04.043>
- Harwood A-E, Smith GE, Cayton T, Broadbent E, Chetter IC. A systematic review of the uptake and adherence rates to supervised exercise programs in patients with intermittent claudication. *Ann Vasc Surg* 2016;**34**:280–9. <https://doi.org/10.1016/j.avsg.2016.02.009>
- Harwood AE, Smith GE, Broadbent E, Cayton T. Access to supervised exercise services for peripheral vascular disease patients. *Bull R Coll Surg Engl* 2017;**99**:207–11. <https://doi.org/10.1308/rcsbull.2017.207>
- GOV.UK. Key Findings, Statistical Digest of Rural England, 2023. <https://www.gov.uk/government/statistics/key-findings-statistical-digest-of-rural-england/key-findings-statistical-digest-of-rural-england> [accessed 12 December 2023].
- GOV.SCOT. People and Communities - Rural Scotland Key Facts 2021. <https://www.gov.scot/publications/rural-scotland-key-facts-2021/pages/2/> [accessed 12 December 2023].
- Bolt LJJ, Jacobs MLYE, Sigterman TA, *et al*. Assessment of behavioral determinants influencing success of supervised exercise therapy in patients with intermittent claudication: a cross sectional survey. *Physiol Behav* 2020;**215**:112732. <https://doi.org/10.1016/j.physbeh.2019.112732>
- Pymer S, Ibeggazene S, Palmer J, *et al*. An updated systematic review and meta-analysis of home-based exercise programs for individuals with intermittent claudication. *J Vasc Surg* 2021;**74**:2076–2085.e20. <https://doi.org/10.1016/j.jvs.2021.03.063>
- Volkmer B, Sekhon M, Bieles J, *et al*. Participants' experiences and acceptability of a home-based walking exercise behaviour-change intervention (MOTivating Structured walking Activity in people with Intermittent Claudication (MOSAIC)). *Physiotherapy* 2024;**122**:70–9. <https://doi.org/10.1016/j.physio.2023.09.002>
- Bearne L, Holmes MG, Bieles J, *et al*. Motivating Structured walking Activity in people with Intermittent Claudication (MOSAIC): protocol for a randomised controlled trial of a physiotherapist-led, behavioural change intervention versus usual care in adults with intermittent claudication. *BMJ Open* 2019;**9**:e030002. <https://doi.org/10.1136/bmjopen-2019-030002>
- Bearne LM, Volkmer B, Peacock J, *et al*. Effect of a home-based, walking exercise behavior change intervention vs usual care on walking in adults with peripheral artery disease. *JAMA* 2022;**327**:1344–55. <https://doi.org/10.1001/jama.2022.3391>
- Office for National Statistics (ONS). Internet users (UK): 2020. <https://www.ons.gov.uk/businessindustryandtrade/itandinternetindustry/bulletins/internetusers/2020#:~:text=1.-,Main%20points,aged%2075%20years%20and%20over.2022> (accessed 12 December 2023).
- Treat-Jacobson D, McDermott MM, Bronas UG, *et al*. Optimal exercise programs for patients with peripheral artery disease: a scientific statement from the American Heart Association. *Circulation* 2019;**139**:e10–e33. <https://doi.org/10.1161/CIR.0000000000000623>
- Abaraogu U, Ezenwankwo E, Dall P, *et al*. Barriers and enablers to walking in individuals with intermittent claudication: a systematic review to conceptualize a relevant and patient-centered program. *PLoS One* 2018;**13**:e0201095. <https://doi.org/10.1371/journal.pone.0201095>
- Abaraogu UO, Ezenwankwo EF, Dall PM, Seenan CA. Living a burdensome and demanding life: a qualitative systematic review of the patients experiences of peripheral arterial disease. *PLoS One* 2018;**13**:e0207456. <https://doi.org/10.1371/journal.pone.0207456>
- Abaraogu UO, Dall PM, Seenan C. Non-operative pain management interventions in patients with intermittent claudication: a protocol for a systematic

- mixed studies review with metaanalysis. *Pain and Rehabilitation* 2016;**41**:17–24. <http://www.ingentaconnect.com/content/ppa/pr/2016/00002016/00000041/art00004>
28. Seenan C, McSwiggan S, Roche PA, Tan C-W, Mercer T, Belch JJF. Transcutaneous electrical nerve stimulation improves walking performance in patients with intermittent claudication. *J Cardiovasc Nurs* 2016;**31**:323–30. <https://doi.org/10.1097/JCN.0000000000000258>
 29. Clover AJ, McCarthy MJ, Hodgkinson K, Bell PRF, Brindle NPJ. Noninvasive augmentation of microvessel number in patients with peripheral vascular disease. *J Vasc Surg* 2003;**38**:1309–12. [https://doi.org/10.1016/s0741-5214\(03\)00895-4](https://doi.org/10.1016/s0741-5214(03)00895-4)
 30. Skivington K, Matthews L, Simpson SA, *et al*. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. *BMJ* 2021;**374**:n2061. <https://doi.org/10.1136/bmj.n2061>
 31. Criqui MH, Denenberg JO, Bird CE, Fronek A, Klauber MR, Langer RD. The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing. *Vasc Med* 1996;**1**:65–71. <https://doi.org/10.1177/1358863X9600100112>
 32. Lewis M, Bromley K, Sutton CJ, McCray G, Myers HL, Lancaster GA. Determining sample size for progression criteria for pragmatic pilot RCTs: the hypothesis test strikes back! *Pilot Feasibility Stud* 2021;**7**:40. <https://doi.org/10.1186/s40814-021-00770-x>
 33. Rollnick S, Miller WR, Butler CC. *Motivational Interviewing in Health Care: Helping Patients Change Behavior*. 2nd ed. The Guilford Press, 2022.
 34. Sekhon M, Cartwright M, Francis JJ. Development of a theory-informed questionnaire to assess the acceptability of healthcare interventions. *BMC Heal Serv Res* 2022;**22**:279. <https://doi.org/10.1186/s12913-022-07577-3>
 35. Clarke CL, Holdsworth RJ, Ryan CG, Granat MH. Free-living physical activity as a novel outcome measure in patients with intermittent claudication. *Eur J Vasc Endovasc Surg* 2013;**45**:162–7. <https://doi.org/10.1016/j.ejvs.2012.11.027>
 36. Dworkin RH, Turk DC, Revicki DA, *et al*. Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). *Pain* 2009;**144**:35–42. <https://doi.org/10.1016/j.pain.2009.02.007>
 37. Nicholas MK. The pain self efficacy questionnaire: taking pain into account. *Eur J Pain* 2007;**11**:153–63.
 38. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: development and validation. *Psychol Assess* 1995;**7**:524–32. <https://doi.org/10.1037/1040-3590.7.4.524>
 39. Chong PFS, Garratt AM, Gollidge J, Greenhalgh RM, Davies AH. The intermittent claudication questionnaire: a patient-assessed condition-specific health outcome measure. *J Vasc Surg* 2002;**36**:764–71.
 40. Moyers TB, Rowell LN, Manuel JK, Ernst D, Houck JM. The Motivational Interviewing Treatment Integrity Code (MITI 4): rationale, preliminary reliability and validity. *J Subst Abuse Treat* 2016;**65**:36–42. <https://doi.org/10.1016/j.jsat.2016.01.001>
 41. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMC Med* 2010;**8**:18. <https://doi.org/10.1186/1741-7015-8-18>
 42. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol* 2006;**3**:77–101. <https://doi.org/10.1191/1478088706qp063oa>

Appendix 1 SPIRIT Checklist



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	1,3, 6-14
Protocol version	3	Date and version identifier	3
Funding	4	Sources and types of financial, material, and other support	17
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1
	5b	Name and contact information for the trial sponsor	17
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	17
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	13, 17
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4-6
	6b	Explanation for choice of comparators	4-6
Objectives	7	Specific objectives or hypotheses	6
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	6
Methods: Participants, interventions, and outcomes			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	7
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8-9
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	14
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	8-10
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	8
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	9-11
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	11-12

Appendix 1 SPIRIT Checklist continued

Section/item	Item No	Description	Addressed on page number
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	8
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	9-10
Methods: Assignment of interventions (for controlled trials)			
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	8
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	8
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	8
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	8, 12-14
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n/a
Methods: Data collection, management, and analysis			
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	11-12
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	11-12
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	14
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	12-14
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	13
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	12
Methods: Monitoring			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	14
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	14
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	14
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	14

Appendix 1 SPIRIT Checklist continued

Section/item	Item No	Description	Addressed on page number
Ethics and dissemination			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	14-15
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	n/a
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	12-13
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	14
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	17
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	14-15
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	14-16
	31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Appendix 3
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a_

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

Appendix 2 CONSORT extension Pilot and Feasibility Trials Checklist



CONSORT 2010 checklist of information to include when reporting a pilot or feasibility trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a pilot or feasibility randomised trial in the title	1
	1b	Structured summary of pilot trial design, methods, results, and conclusions (for specific guidance see CONSORT abstract extension for pilot trials)	3
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale for future definitive trial, and reasons for randomised pilot trial	4-6
	2b	Specific objectives or research questions for pilot trial	4-6
Methods			
Trial design	3a	Description of pilot trial design (such as parallel, factorial) including allocation ratio	7
	3b	Important changes to methods after pilot trial commencement (such as eligibility criteria), with reasons	n/a
Participants	4a	Eligibility criteria for participants	7
	4b	Settings and locations where the data were collected	7-8
	4c	How participants were identified and consented	7-8
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	8-9
Outcomes	6a	Completely defined prespecified assessments or measurements to address each pilot trial objective specified in 2b, including how and when they were assessed	9-12
	6b	Any changes to pilot trial assessments or measurements after the pilot trial commenced, with reasons	N/A
	6c	If applicable, prespecified criteria used to judge whether, or how, to proceed with future definitive trial	N/A
Sample size	7a	Rationale for numbers in the pilot trial	8-9
	7b	When applicable, explanation of any interim analyses and stopping guidelines	14-15
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	8
	8b	Type of randomisation(s); details of any restriction (such as blocking and block size)	8
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	8
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	8
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	8, 12-14
	11b	If relevant, description of the similarity of interventions	n/a
Statistical methods	12	Methods used to address each pilot trial objective whether qualitative or quantitative	12-14
Results			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were approached and/or assessed for eligibility, randomly assigned, received intended treatment, and were assessed for each objective	N/A
	13b	For each group, losses and exclusions after randomisation, together with reasons	N/A
Recruitment	14a	Dates defining the periods of recruitment and follow-up	N/A
	14b	Why the pilot trial ended or was stopped	N/A
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	N/A
Numbers analysed	16	For each objective, number of participants (denominator) included in each analysis. If relevant, these numbers should be by randomised group	N/A
Outcomes and estimation	17	For each objective, results including expressions of uncertainty (such as 95% confidence interval) for any estimates. If relevant, these results should be by randomised group	N/A
Ancillary analyses	18	Results of any other analyses performed that could be used to inform the future definitive trial	N/A
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	N/A
	19a	If relevant, other important unintended consequences	N/A
Discussion			
Limitations	20	Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about feasibility	N/A
Generalisability	21	Generalisability (applicability) of pilot trial methods and findings to future definitive trial and other studies	N/A
Interpretation	22	Interpretation consistent with pilot trial objectives and findings, balancing potential benefits and harms, and considering other relevant evidence	N/A
	22a	Implications for progression from pilot to future definitive trial, including any proposed amendments	N/A
Other information			
Registration	23	Registration number for pilot trial and name of trial registry	17
Protocol	24	Where the pilot trial protocol can be accessed, if available	N/A
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	17
	26	Ethical approval or approval by research review committee, confirmed with reference number	17

Citation: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ*. 2016;355. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) license (<http://creativecommons.org/licenses/by/3.0/>), which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.

*We strongly recommend reading this statement in conjunction with the CONSORT 2010, extension to randomised pilot and feasibility trials, Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up-to-date references relevant to this checklist, see www.consort-statement.org.